Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Japanese study of talquetamab in relapsed or refractory multiple myeloma
jRCT2061210001Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of talquetamab in multiple myeloma (MM) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events and 2 more. Started Jun 2021; status: completed.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2061210001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210001.